How to buy Addex Therapeutics stock (ADXN)

Addex Therapeutics is a biotechnology business based in the US. Addex Therapeutics shares (ADXN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.90 – a decrease of 1.25% over the previous week. Addex Therapeutics employs 23 staff and has a trailing 12-month revenue of around $863,232.

Our top picks for where to buy Addex Therapeutics stock

Buy Addex Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Addex Therapeutics stock price (NASDAQ: ADXN)

Use our graph to track the performance of ADXN stocks over time.

Addex Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$7.90
52-week range	$5.39 - $27.90
50-day moving average more info button	$9.34
200-day moving average more info button	$10.28
Wall St. target price	$30.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-21.51

Is it a good time to buy Addex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Addex Therapeutics price performance over time

Historical closes compared with the close of $7.9 from 2024-12-20

1 week (2024-12-13)	-1.25%
1 month (2024-11-22)	4.91%
3 months (2024-09-20)	-19.72%
6 months (2024-06-21)	-0.94%

1 year (2023-12-22)	44.95%
2 years (2022-12-22)	-28.75%
3 years (2021-12-22)	133.8
5 years (2019-12-18)	N/A

Addex Therapeutics financials

Revenue TTM	$863,232
Gross profit TTM	$1.4 million
Return on assets TTM	-61.71%
Return on equity TTM	-126.29%
Profit margin	500.17%
Book value	$0.01
Market Capitalization more info button	$8.1 million

TTM: trailing 12 months

Addex Therapeutics share dividends

We're not expecting Addex Therapeutics to pay a dividend over the next 12 months.

Have Addex Therapeutics's shares ever split?

Addex Therapeutics's shares were split on a 1:20 basis on 22 October 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Addex Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Addex Therapeutics shares which in turn could have impacted Addex Therapeutics's share price.

Addex Therapeutics share price volatility

Over the last 12 months, Addex Therapeutics's shares have ranged in value from as little as $5.39 up to $27.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Addex Therapeutics's is 1.874. This would suggest that Addex Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Addex Therapeutics overview

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Frequently asked questions

null
What percentage of Addex Therapeutics is owned by institutions?
Currently 0.169% of Addex Therapeutics shares are held by institutions. How many people work for Addex Therapeutics?
Latest data suggests 23 work at Addex Therapeutics. When does the fiscal year end for Addex Therapeutics?
Addex Therapeutics's fiscal year ends in December. Where is Addex Therapeutics based?
Addex Therapeutics's address is: Chemin des Mines, 9, Geneva, Switzerland, 1202 What is Addex Therapeutics's ISIN number?
Addex Therapeutics's international securities identification number is: US00654J1079 What is Addex Therapeutics's CUSIP number?
Addex Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00654J107